Shares of Health Care sector company Novavax moved 2.7% today, and are now trading at a price of $6.99. The mid-cap stock's daily volume was 4,286,018 compared to its average volume of 9,483,668. The S&P 500 index returned a -0.0% performance.
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. The company is based in Gaithersburg and has 1,992 full time employees. Its market capitalization is $704,814,464.
5 analysts are following Novavax and have set target prices ranging from $5.0 to $38.0 per share. On average, they have given the company a rating of hold. At today's prices, NVAX is trading -66.09% away from its average analyst target price of $20.6 per share.
Over the last year, NVAX shares have gone down by -68.0%, which represents a difference of -80.0% when compared to the S&P 500. The stock's 52 week high is $25.66 per share and its 52 week low is $5.61. Novavax has averaged free cash flows of $-228838333.3 over the last 6 years, with a mean growth rate of -26.2%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | -654,055 | 99,004 | -753,059 | -62.44 |
| 2022 | -415,937 | 47,654 | -463,591 | -274.64 |
| 2021 | 322,946 | 57,486 | 265,460 | 373.21 |
| 2020 | -42,541 | 54,622 | -97,163 | 29.84 |
| 2019 | -136,623 | 1,857 | -138,480 | 25.63 |
| 2018 | -184,825 | 1,372 | -186,197 |
